Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL ...
On May 21, 2025, Vigil announced that it had agreed to be acquired by Sanofi at an upfront price of $8.00 per share in cash plus a non-transferable contingent value right (CVR) worth an additional ...
Vigil Neuroscience routinely posts information that may be important to investors in the 'Investors' section of its website at https://www.vigilneuro.com. The company encourages investors and ...
Draig Therapeutics has announced the appointment of Ivana Magovčević-Liebisch as President and Chief Executive Officer. She ...
- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 - - Extends projected ...
Vigil Neuroscience, Inc. (VIGL) closed the last trading session at $7.93, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback